retatrutide obesity triple hormone receptor agonist Retatrutide—A Game Changer in Pharmacotherapy Media Centre | EASD
Description
Recently, evidence has demonstrated a role of GLP-1 receptor (GLP-1R) agonists, commonly used in the treatment of type 2 diabetes, may have therapeutic potential in AD
GHRP, G protein-coupled growth hormone secretagogue receptor
The interaction between growth hormone pathway activation and triple-receptor incretin agonism creates metabolic variables that must be tracked consistently
Candidates for GLP1 weight loss medications typically have a body mass index (BMI) in the overweight or obese range and may have weightrelated health concerns such as prediabetes, type 2 diabetes, high blood pressure, or elevated cholesterol
Past, present, and future of CRISPR genome editing technologies
Snabb verblick: Vad gr GLP-1
